Ascendiant Capital Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has initiated coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with a Buy rating and a price target of $11.
August 05, 2024 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendiant Capital has initiated coverage on Mira Pharmaceuticals with a Buy rating and a price target of $11.
The initiation of coverage with a Buy rating and a price target of $11 by Ascendiant Capital is likely to positively impact Mira Pharmaceuticals' stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100